ArticleJAMA network open2022

Navigating Systemic Therapeutic Options for First-Line Metastatic Hormone Receptor-Positive, ERBB2-Negative Breast Cancer Treatment.

Yehoda M Martei et al.PubMed ↗Publisher ↗

No numbers read from the abstract.